keep in mind on cydy evaluation if our mos for our mTNBC trial patients exceeds trodelvy 12.9 -13 mos then our cancer value should be at least equal to the $21 billion gild paid. of course the argument against this evaluation is that trodelvy received accelerated fda approval in 2020 but to date our mTNBC has not-i think our trial officially ends in august 2022? at this time a buyout ok but imo a partnership/s is far better cause bp would only want to steal leronlimab.we should be worth at least $40- $50 or more a share since we are not a 1 trick pony molecule but now leronlimab features 4 platform areas-hiv,cancer,nash,and covid with further platform potential.